Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.

In conclusion, we show that the introduced immuno-based assays enable the quantitative assessment of glucocerebrosidase and α-synuclein parameters in post-mortem brain. In the substantia nigra, reduced glucocerebrosidase levels contribute to the increase in α-synuclein levels and to PD-DLB disease manifestation partly by increasing its glycolipid substrate glucosylsphingosine. This interrelation between glucocerebrosidase, glucosylsphingosine and α-synuclein parameters supports the hypothesis that glucocerebrosidase acts as a modulator of PD-DLB. PMID: 30236861 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30236861?dopt=Abstract

Source: Neurobiology of Disease - September 17, 2018 Category: Neurology Authors: Gündner AL, Duran-Pacheco G, Zimmermann S, Ruf I, Moors T, Baumann K, Jagasia R, van de Berg WDJ, Kremer T Tags: Neurobiol Dis Source Type: research